Secondly, even in diseases such as CLL, where targeted agents such as ibrutinib have largely replaced chemotherapeutic strategies, outcomes are significantly worse among patients with del17p, mutated TP53 [21, 22] or complex karyotypes [23] associated with del17p [24]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.